Mendus: First Alison phase I data aligns with our expectations - Redeye

Redeye briefly comments on Mendus presenting first clinical data from its ALISON phase I trial with lead candidate DCP-001 in ovarian cancer maintenance therapy in an abstract published ahead of ESGO 2022. Good safety and tolerability align with our expectations. In addition, we are encouraged by promising preclinical data with DCP-001 in ovarian cancer models.

Länk till analysen i sin helhet: https://www.redeye.se/research/858367/mendus-first-alison-phase-i-data-aligns-with-our-expectations?utm_source=finwire&utm_medium=RSS